A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes
Time: 3:00 pm
day: Day Two – Track B – 2
Details:
- Utilizing data from human microbiota transplantation studies and machine learning to develop novel investigational microbiome therapeutics and retire risk early
- An update on Finch’s clinical and preclinical pipeline
- An update on latest clinical data supporting Finch’s lead product candidate, CP101, for the prevention of recurrent C. difficile infection
Speakers:
Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro’s computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This…Read more